SUBSCRIBE
SUBSCRIBE

Clinical Oncology Next-generation Sequencing Market: Size and Share of Key Segments Report

May 13, 2020 | 
7 min read

Next Generation Sequencing or NGS is an outstanding technology that arranges massive DNA strands through enormous parallelization.

Next Generation Sequencing or NGS is an outstanding technology that arranges massive DNA strands through enormous parallelization. It is otherwise called high throughput sequencing. The innovation limits the need for section cloning which is utilized in Sanger sequencing of genomes. The key benefits that NGS offers over Sanger’s sequencing technique are swift processes, precise results, and ease of operations even from low sample inputs. With the advancement of new technologies and treatment to cure cancer, the clinical oncology next generation sequencing market has enormous potential in coming years.

The significant explanation that is driving the development of the clinical oncology next generation sequencing market are the decrease in the expense of capital and sequencing and improved administrative conditions & repayment for NSG diagnostics. Likewise, the expanding use of precision drugs and molecular diagnostics alongside proposition of huge sequencing ventures by government and private sector are few more factors that are driving the growth of clinical oncology next generation sequencing market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1232

Some of the Recent Developments in Global Clinical Oncology Next Generation Sequencing Market?

  • In 2019, Agilent Technologies, a leader in global clinical oncology-next generation sequencing market acquired BioTek Instruments. The acquisition aims to enhance the production capacity of company and research and development that shall help the company to major share of the global clinical oncology-next generation sequencing market. This shall also allow the company to gain access to the latest technologies of the BioTek making it one of most prominent company in the global clinical oncology-next generation sequencing market.

Next Generation Sequencing or NGS is an outstanding technology that arranges massive DNA strands through enormous parallelization. It is otherwise called high throughput sequencing. The innovation limits the need for section cloning which is utilized in Sanger sequencing of genomes. The key benefits that NGS offers over Sanger’s sequencing technique are swift processes, precise results, and ease of operations even from low sample inputs. With the advancement of new technologies and treatment to cure cancer, the clinical oncology next generation sequencing market has enormous potential in coming years.

The significant explanation that is driving the development of the clinical oncology next generation sequencing market are the decrease in the expense of capital and sequencing and improved administrative conditions & repayment for NSG diagnostics. Likewise, the expanding use of precision drugs and molecular diagnostics alongside proposition of huge sequencing ventures by government and private sector are few more factors that are driving the growth of clinical oncology next generation sequencing market.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=1232&ltype=S

Some of the Recent Developments in Global Clinical Oncology Next Generation Sequencing Market?

  • In 2019, Agilent Technologies, a leader in global clinical oncology-next generation sequencing market acquired BioTek Instruments. The acquisition aims to enhance the production capacity of company and research and development that shall help the company to major share of the global clinical oncology-next generation sequencing market. This shall also allow the company to gain access to the latest technologies of the BioTek making it one of most prominent company in the global clinical oncology-next generation sequencing market.

Global Clinical Oncology Next-generation Sequencing Market – Overview

Next generation sequencing is also known as non-Sanger based high throughput DNA sequencing technology. This term is particularly used for defining advanced and modern sequencing technologies such as Roche 454 Sequencing, Illumina (Solexa) Sequencing, Proton/PGM sequencing, and SOLiD sequencing among others. Billions of DNA strands are chained in parallel that provide considerable more throughput. The clinical oncology-next generation sequencing market is thus making use of such new sequencing technologies for profiling cancer. The leading players in the global market are concentrating more on acquisitions, mergers, and strategic joint ventures. This has thus helped the developing nations to offer support to set up new centers for research and development activities.

Global Clinical Oncology Next-generation Sequencing Market – Notable Developments

Some of the notable developments in the global clinical oncology-next generation sequencing market are given below:

  • In April 2017, Genomatix Inc. announced that the company has successfully acquired funding from the Bavarian Ministry of Economic Affairs and Media, Energy, and Technology for the Multiple Integration and Data Annotation Study (MIDAS) project. The aim of the project and funding is to enhance the characterization of rare diseases such as cancer in children and devise effective treatment.
  • In August 2019, Agilent Technologies, a prominent name in the global clinical oncology-next generation sequencing market announced that the company has successfully taken over BioTek Instruments. This acquisition is expected to bolster the production capacity of Agilent Technologies. The aim of the acquisition was to complement the research in the field of next generation sequencing by developing effective technologies for the same.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1232

Some of the leading vendors in the global next-generation sequencing market are:

  • GATC Biotech Ag
  • Oxford Nanopore Technologies Ltd.
  • Macrogen Inc.
  • Life technologies Corp.
  • DNASTAR Inc.
  • Myriad Genetics
  • Exosome Diagnostics
  • Biomatters Ltd.
  • BGI (Beijing Genomics Institute)
  • Qiagen NV, Perkin Elmer, Inc.
  • Pacific Bioscience, Inc.
  • Partek, Inc.
  • Bio-Rad Laboratories, Inc.

Global Clinical Oncology Next-generation Sequencing Market – Drivers and Restraints

Among the several growth influencing factors for the clinical oncology-next generation sequencing market, the biggest factor is the increasing adoption of genomic-centric pharmacology in the treatment of cancer. The clinical oncology-next generation sequencing market makes use of the most advanced genomic techniques and technologies to investigate the genetic changes that occur due to the spreading of cancer in the body. The rapid development and innovations in this segment is thus driving the overall growth of the global clinical oncology-next generation sequencing market.

In addition to this, there has been a considerable rise in investments and funding to the research and development centers concentrating on finding new solutions in sequencing. This factor coupled with expanding healthcare budgets of several developed nations is also providing a big help to the global clinical oncology-next generation sequencing market.

Moreover, the practicing medical professionals and doctors are now familiar with clinical oncology-next generation sequencing and are increasingly using the same for diagnosis and treatment of cancer. This has not only spreading the awareness among the common masses but also helping to scale up the uptake of the global market. Oncologists these days are more reliant clinical oncology-next generation sequencing to select drugs or their combination for treating patients.

Global Clinical Oncology Next-generation Sequencing Market – Geographical Outlook

There are five main geographical segments of the global clinical oncology-next generation sequencing market viz. Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. Of these, the global market is expected to be dominated by North America over the course of the given forecast period of 2018 to 2028. This growth of the market is due to heavy spending on the development of new R&D facilities that work on clinical oncology-next generation sequencing. In addition to this, the presence of several leading players in the global market has also worked in favor for the growth of the North America market.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/